CD20 Monoclonal Antibody

See Monoclonal Antibody-Mediated Chemotherapy
CD20 Antigens
1. CD20 Antigens are phosphoproteins found only on the surface of B-Cells including Leukemia, Lymphoma (but not B-Cell precursors)
2. Regulate transmembrane Calcium conductance
3. Plays a role in B-Cell Activation and proliferation, as well as complement-dependent cytotoxicity
Anti-CD20 Monoclonal Antibody
1. Recombinant human Monoclonal Antibody directed against the CD20 Antigen cell surface marker
2. Bind CD20 and triggers a cytotoxic immune response, depleting CD20 positive B Cells

Rituximab (Rituxan)
1. See Rituximab
2. Used in Non-Hodgkin's Lymphoma (as well as several other Lymphomas and Leukemias)
3. Also used in Refractory Rheumatoid Arthritis, Granulomatosis with Polyangiitis
4. Risk of severe infusion reactions and severe mucocutaneous reactions
5. Also risk of PML, Tumor Lysis Syndrome, Hepatitis B reactivation and Bowel Obstruction and perforation
6. Also risk of Acute Kidney Injury, Cardiac Arrhythmia and severe cytopenia
Ofatumumab (Arzerra, Kesimpta)
1. Used in Chronic Lymphocytic Leukemia (Arzerra) and Multiple Sclerosis (Kesimpta)
2. Risk of severe infusion reactions, Severe infections, Hepatitis B reactivation
Obinutuzumab (Gazyva)
1. Used in CLL, Follicular Lymphoma
2. Risk of Hepatitis B reactivation, PML, DIC, Tumor Lysis Syndrome, infusion reactions, severe infections, cytopenias,
Ocrelizumab (Ocrevus)
1. Indicated for Multiple Sclerosis (relapsing, and primary progressive)
  1. First-line only in primary progresive MS (only one FDA approved in primary progressive MS)
2. Pretreat doses with Methylprednisolone and Diphenhydramine (or other Antihistamine) 30 to 60 minutes before dose
3. Adults with MS
  1. Load: 300 mg IV infusion over 3.5 hours for 2 doses, 2 weeks apart
  2. Maintenance: 600 mg IV infusion over 3.5 hours every 6 months

Ibritumomab tiuxetan (Zevalin)
1. Used for Non-Hodgkin's Lymphoma
2. Risk of severe infusion reactions, cytopenias and secondary malignancies
3. Conjugate of CD20 Monoclonal Antibody (Ibritumomab) and a radioisotope chelation site (tiuxetan)
  1. Tiuxetan is bound to Iridium-111 or yttrium Y-90
  2. Delivers cytotoxic dose of radiation to B Cells with CD20 cell surface marker
Tositumomab-Iodine 131 (Bexxar)
1. Used for Non-Hodgkin's Lymphoma
2. Risk of severe infusion reactions, cytopenia, secondary malignancy, Hypothyroidism
3. Conjugate of CD20 Monoclonal Antibody (Tositumomab) and a radioisotope, Iodine-131
  1. Delivers cytotoxic dose of radiation to B Cells with CD20 cell surface marker

Severe infusion reactions including Anaphylaxis (Rituximab, Ofatumumab, Ibritumomab, Obinutuzumab, Tositumomab)
Severe mucocutaneous syndrome (Rituximab, Ibritumomab)
Progressive Multifocal Leukoencephalopathy (Rituximab, Ofatumumab, Obinutuzumab)
Tumor Lysis Syndrome (Rituximab, Obinutuzumab)
Hepatitis B reactivation (Rituximab, Ofatumumab, Obinutuzumab)
Acute Kidney Injury (Rituximab)
Cardiac Arrhythmia (Rituximab)
Severe cytopenia (Rituximab, Ofatumumab, Ibritumomab, Obinutuzumab, Tositumomab)
Bowel Obstruction and perforation (Rituximab, Ofatumumab)
Severe infections (Rituximab, Obinutuzumab)
Hypothyroidism (Tositumomab-I131)
Secondary malignancy (Ibritumomab-tiuxetan, Tositumomab-I131)
1. Acute Myelogenous Leukemia
2. Myelodysplastic Syndrome

Avoid in Lactation
Avoid in pregnancy (all trimesters, Pregnancy category X)
1. Use reliable Contraception

Vaccines
1. Give Live Attenuated Vaccines at least 6 weeks before dosing
2. Give non-Live Vaccines at least 2 weeks prior to dosing